was climbing 5% to $60.80 in Instinet trading before the bell, a day after the biotech company provided Wall Street with an
optimistic forecast for 2002.
The company said it expects earnings per share to grow in the low-20% range in 2002. Analysts are expecting the company to post earnings of $1.19 a share this year and $1.40 in 2002. Earnings growth of even 20% implies a bottom line of about $1.43 for next year.
The forecast excludes the effects of a possible new application for Aranesp and pegfilgrastim, a long-acting version of Neupogen.